Amphipathic helices support function of blood coagulation factor IXa.
Blood coagulation factor IXa gains proteolytic efficiency upon binding to a phospholipid membrane. We have found that an amphipathic, membrane-binding peptide from the C2 domain of factor VIII, fVIII(2303)(-23), enhances proteolytic efficiency of factor IXa in the absence of phospholipid membranes. This enhancement is the result of a reduction in the K(M) for the substrate, factor X, with little effect on the k(cat). Enhanced function requires interaction of the gamma-carboxyglutamic acid (Gla) domains of factor IXa and factor X since (i) a synthetic peptide comprising the Gla domain of factor IXa and antibodies directed to the Gla domain of factor IXa inhibit this acceleration, (ii) the acceleration is Ca(II) dependent, and (iii) conversion of Gla-domainless factor X is not affected by the presence of fVIII(2303)(-23). The effect of fVIII(2303)(-23) on factor IXa parallels the enhanced function produced by phosphatidylserine-containing bilayers, and fVIII(2303)(-23) does not further enhance function of factor IXa when phospholipid vesicles are present. The critical feature of fVIII(2303)(-23) is apparently its amphipathic helix-forming structure [Gilbert, G. E., and Baleja, J. D. (1995) Biochemistry 34, 3022-3031] because other alpha-helical peptides such as a homologous peptide from the C2 domain of factor V and melittin have similar effects. Diastereomeric analogues of fVIII(2303)(-23) and melittin, which have reduced helical content, do not support factor IXa activity. A truncated peptide of fVIII(2303)(-23) with three C-terminal residues deleted retains alpha-helical content but loses capacity to enhance factor X cleavage, suggesting that a minimum length of alpha-helix is required. Although these results probably do not illuminate the physiologic function of the factor VIII peptide corresponding to fVIII(2303)(-23), they demonstrate a novel, membrane-mimetic role of amphipathic helical peptides in supporting function of factor IXa.
Blostein
M D
MD
Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Rigby
A C
AC
Furie
B C
BC
Furie
B
B
Gilbert
G E
GE
D015055:1-Carboxyglutamic Acid / Q000737:chemistry; D000595:Amino Acid Sequence; D002352:Carrier Proteins / Q000737:chemistry / Q000378:metabolism; D002384:Catalysis; D003435:Crotalid Venoms; D005164:Factor IX / Q000737:chemistry / Q000378:metabolism; D015949:Factor IXa / Q000737:chemistry* / Q000378:metabolism; D005169:Factor VIII / Q000737:chemistry / Q000378:metabolism; D005170:Factor X / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008565:Membrane Proteins / Q000737:chemistry / Q000378:metabolism; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry* / Q000378:metabolism; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D030162:Reptilian Proteins; D013329:Structure-Activity Relationship
D002352:Carrier Proteins; D003435:Crotalid Venoms; D008565:Membrane Proteins; D010446:Peptide Fragments; D030162:Reptilian Proteins; C070302:factor IX-factor X-binding protein, Crotalinae; D015055:1-Carboxyglutamic Acid; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D015949:Factor IXa